Cervical Cytology

BD SurePath™ Pap Test



BD SurePath™ liquid-based Pap test

BD SurePath™ liquid-based Pap test


The BD SurePath™ liquid-based Pap test is an FDA approved thin-layer cell preparation process intended for use in the screening and detection of cervical cancer, pre-cancerous lesions, atypical cells and all other cytologic categories as defined by The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses.1

FOCUS: Cervical Disease Detection Combined with Laboratory Efficiency.

BD SurePath™ liquid-based Pap test:

  • Can claim the greatest increase in disease detection of all Pap tests (64.4% increase in HSIL+ lesions detection2 in comparison to the conventional Pap smear).
  • Significantly reduces Unsatisfactory and Satisfactory But Limited By (SBLB) cases3 for potentially fewer patient callbacks.
  • Removes most debris (e.g. blood, mucous, lubricant, inflammation) with maximum confidence in the result due to the proprietary BD SurePath™ Cell Enrichment process in your lab. Doctors are confident that their samples are handled properly in the lab.

Try BD SurePath™ Pap test in your laboratory.
1 Kurman RJ, Solomon D (editors). The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses: Definitions, Criteria and Explanatory Notes for Terminology and Specimen Adequacy. New York, Springer Verlag, 1994.
2 BD PrepStain™ Slide Processor Product Insert. Direct-to-Vial study population.
3 BD PrepStain™ Slide Processor Product Insert. Split-sample study population.